Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 6/20 | 0.48 |
| ▸ | HTR2B | P41595 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | LIG1 | P18858 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PPOX | P50336 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10399423 | 0.82 | HTR2C (0.51) | TSHRGAAHTR2CHTR2BHTR2A | |
| SCHEMBL30826232 | 0.82 | HTR2C (0.51) | TSHRGAAHTR2CHTR2BHTR2A | |
| SCHEMBL5957107 | 0.81 | TSHR (0.62) | TSHRGAAHTR2CHTR2BHSD17B10 | |
| SCHEMBL2520491 | 0.79 | TSHR (0.44) | TSHRGAAHTR2CHTR2BHTR2A | |
| SCHEMBL23216493 | 0.78 | HTR2C (0.49) | TSHRGAAHTR2CHTR2BHTR2A | |
| SCHEMBL5485838 | 0.78 | TSHR (0.39) | TSHRGAAHSD17B10HPGDLIG1 | |
| SCHEMBL29782302 | 0.78 | HTR2C (0.49) | TSHRGAAHTR2CHTR2BHTR2A | |
| SCHEMBL30826270 | 0.77 | HTR2C (0.48) | TSHRGAAHTR2CHTR2BHTR2A | |
| Triclofenol SCHEMBL10399422 | 0.74 | TSHR (0.56) | TSHRGAAHTR2CHTR2BHTR2A | |
| SCHEMBL6707110 | 0.74 | MAOB (0.50) | TSHRGAAHSD17B10HPGDLIG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486992-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2013-07-16 | — | — | US | disclosed |
| US-8268881-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2012-09-18 | — | — | US | disclosed |
| US-20110251164-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2011-10-13 | — | — | US | disclosed |
| US-7772223-B2 | 5-Methyl-5-(3-phenoxyazetidin-1-yl)-2,2-diphenylhexanamide, used for the treatment of respiratory system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis and emphysema | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-02-04 | — | — | US | disclosed |
| EP-1928821-B1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| EP-1928821-A1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
| WO-2007034325-A1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251164-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | TSHR 104/4885GAA 3248/4885HTR2C 195/4885 |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | TSHR 104/4885GAA 3248/4885HTR2C 195/4885 |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | TSHR 104/4885GAA 3248/4885HTR2C 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.